Phase 1 Peripheral Neuropathy Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have MDS (myelodysplastic syndrome) or a related blood condition called dysplastic CMML that has come back or stopped responding to treatment, with less than 20% blast cells (abnormal cells) in the blood or bone marrow, and who have already received at least one standard treatment (or have run out of locally available treatment options).
• The diagnosis must have been confirmed through laboratory testing of tissue samples, classified according to a specific 2016 international standard for blood cancers.
• People who have an overall health and activity level rated as reasonably functional (a score of 2 or lower on a standard medical scale used to measure how well a person can carry out daily activities).
• People whose condition is causing symptoms that need treatment and can be measured to assess whether the trial is working.
• People who are willing to provide a bone marrow sample at the start of the trial.
• People who are willing to use contraception as required by local rules and the trial's guidelines.
• Women who are able to become pregnant must have a negative blood pregnancy test at the screening stage before joining.

Who may not be able to join:

• People who have previously been treated with a class of drugs called IRAK inhibitors or inflammasome pathway inhibitors (confirm with trial site if unsure whether a past treatment falls into these categories).
• People who have received most types of cancer treatment (except a drug called hydroxyurea) within 15 days before the first trial dose.
• People who have taken certain medications known to affect how the body processes drugs (called strong or moderate CYP3A inhibitors) within 15 days before the first trial dose.
• People who have had major surgery within 28 days before the first trial dose, or who are still recovering from surgery.
• People who have taken medications known to affect heart rhythm in a specific way (prolonging the QTc interval, with a risk of a serious irregular heartbeat called Torsades de Pointes) within 15 days before the first trial dose.
• People who have taken immune-suppressing medications (including those used to prevent a complication called Graft-Versus-Host Disease) within 28 days before the first trial dose, or certain steroid medications above a set dose within 15 days before the first trial dose.
• People who have received live vaccines within 28 days before the first trial dose.
• People who currently have a serious active bleeding event.
• People with other significant health conditions or test results that the trial team considers would make participation unsafe or unsuitable.
• People whose heart electrical activity, measured by a specific test (ECG), shows a reading above a set threshold (confirm with trial site for details on the exact measurement used).
• People who have had bleeding inside the brain within the 6 months before the first trial dose.
• People with active digestive system disease or another condition that could significantly affect how the trial medication is absorbed or processed by the body.
• People with a history of a non-blood-related cancer (some exceptions may apply — confirm with trial site).
• People who still have unresolved significant side effects (Grade 2 or higher) from previous cancer treatments (some exceptions may apply — confirm with trial site).
• People already enrolled in another clinical trial (some exceptions may apply — confirm with trial site).
• People with a known allergy or sensitivity to the trial medication or any of its ingredients.

Important: Always verify eligibility with the trial site directly before applying.